Federal Register / Vol. 74, No. 174 / Thursday, September 10, 2009 / Notices 46609 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Aneurysm 

Trial. 

Date: October 1, 2009. 

Time: 6 p.m. to 7 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: Alicja L. Markowska, PhD, 

DSC, Scientific Review Officer, Scientific 

Review Branch, National Institute on Aging, 

7201 Wisconsin Avenue, Gateway Building, 

Suite 2C212, Bethesda, MD 20892, 301–496– 

9666, markowska@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Osteoporosis 

Trial. 

Date: October 2, 2009. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One Metro 

Center, Bethesda, MD 20814. 

Contact Person: Alicja L. Markowska, PhD, 

DSC, Scientific Review Officer, Scientific 

Review Branch, National Institute on Aging, 

7201 Wisconsin Avenue, Gateway Building, 

Suite 2C212, Bethesda, MD 20892, 301–496– 

9666, markowska@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Genetic 

Modification of Aged and Diseased Muscle. 

Date: October 19, 2009. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 2C212, 7201 Wisconsin 

Avenue, Bethesda, MD 20892 (Telephone 

Conference Call) 

Contact Person: Elaine Lewis, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, Gateway 

Building, Suite 2C212, MSC–9205, 7201 

Wisconsin Avenue, Bethesda, MD 20892, 

301–402–7707, elainelewis@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Molecular 

Cause of Maturing Deterioration. 

Date: November 3, 2009. 

Time: 2 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Gateway Building, 2C212, 7201 Wisconsin 

Avenue, Bethesda, MD 20892 (Telephone 

Conference Call) 

Contact Person: Bita Nakhai, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, Gateway 

Bldg., 2C212, 7201 Wisconsin Avenue, 

Bethesda, MD 20814, 301–402–7701, 

nakhaib@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Principle of 

Stem Cell Maturation. 

Date: November 4, 2009. 

Time: 12 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Gateway Building, 2C212, 7201 Wisconsin 

Avenue, Bethesda, MD 20892 (Telephone 

Conference Call) 

Contact Person: Bita Nakhai, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, Gateway 

Bldg., 2C212, 7201 Wisconsin Avenue, 

Bethesda, MD 20814, 301–402–7701, 

nakhaib@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: September 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–21789 Filed 9–9–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Hematology and Pathology Devices 

Panel of the Medical Devices Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Hematology and 

Pathology Devices Panel of the Medical 

Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on October 22 and 23, 2009, from 

8 a.m. to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, Salons A, B, and C, 

620 Perry Pkwy., Gaithersburg, MD. 

Contact Person: Louise E. Magruder, 

Center for Devices and Radiological 

Health, Food and Drug Administration, 

10903 New Hampshire Ave., Silver 

Spring, MD 20993, 301–796–6175, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014512515. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On October 22 and 23, 2009, 

the committee will discuss and make 

recommendations on public health 

issues related to the use of digital whole 

slide imaging systems to replace 

conventional light microscopy for 

diagnostic surgical pathology. In the 

scope of this meeting, digital pathology 

is defined as converting what can be 

observed by conventional light 

microscopy on histologic glass slides 

into digital whole slide images via 

digital scanners; viewing these images 

via a computer monitor to render 

pathologic diagnosis of the lesion of 

interest; and digitally archiving and 

retrieving these images. The committee 

will not be discussing computer-assisted 

image analysis or remote real-time 

microscopy. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available on the FDA Internet under the 

appropriate date at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.com. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 15, 2009. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. each day. Those 

desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before October 

1, 2009. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 


erowe on DSK5CLS3C1PROD with NOTICES
46610 Federal Register / Vol. 74, No. 174 / Thursday, September 10, 2009 / Notices 

notify interested persons regarding their 

request to speak by October 8, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact AnnMarie 

Williams, Conference Management 

Staff, 301–796–5966, at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 4, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–21810 Filed 9–9–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Amendment—Public Meeting 

of the AHRQ National Advisory Council 

for Healthcare Research and Quality 

Subcommittee On Quality Measures 

for Children’s Healthcare in Medicaid 

and Children’s Health Insurance 

Programs 

With this correction notice, the 

Agency for Healthcare Research and 

Quality (AHRQ) informs public of an 

Amendment made to the notice subject 

mentioned above which was published 

on August 20, 2009, Vol. 74, No. 160, 

pages 42079–42080, The amendment is 

to add at the end of section 

SUPPLEMENTARY INFORMATION, the 

following: ‘‘As previously noted, the 

meeting is open to the public and can 

also be joined via Webcast. The link to 

online registration for Webcast is 

http://www.ConnectLive.com/events/ 

AHRQ2009.’’ 

Dated: September 3, 2009. 

Carolyn M. Clancy, 

Director. 

[FR Doc. E9–21690 Filed 9–9–09; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Ethics Subcommittee, Advisory 

Committee to the Director, Centers for 

Disease Control and Prevention (CDC) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention announces the 

following Subcommittee meeting: 

Time and Date: 10:30 a.m.–12:30 p.m., 

September 24, 2009. 

Place: The teleconference call will 

originate at the Centers for Disease Control 

and Prevention in Atlanta, Georgia. Please 

see ‘‘Supplementary Information’’ for details 

on accessing the teleconference. 

Status: Open to the public, teleconference 

access limited only by availability of 

telephone ports. The public is welcome to 

participate during the public comment 

period which is tentatively scheduled from 

12:15 p.m.–12:25 p.m. 

Purpose: The Ethics Subcommittee will 

provide counsel to the ACD, CDC, regarding 

a broad range of public health ethics 

questions and issues arising from programs, 

scientists and practitioners. 

Matters To Be Discussed: The 

teleconference agenda will include ethical 

guidance for ventilator distribution during a 

pandemic, update on CDC’s public health 

ethics activities, and follow-up on 

outstanding activities/reports. 

Agenda items are subject to change as 

priorities dictate. 

Supplementary Information: This 

conference call is scheduled to begin at 

10:30 a.m. To participate in the 

teleconference, please dial 1/866/919– 

3560 and enter conference code 

4168828. You will then be automatically 

entered into the call. 

Contact Person for More Information: Drue 

Barrett, PhD, Designated Federal Officer, 

Ethics Subcommittee, CDC, 1600 Clifton 

Road, NE., M/S D–50, Atlanta, Georgia 

30333. Telephone (404/639–4690. E-mail: 

dbarrett@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: September 1, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–21920 Filed 9–9–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Clinical Resources. 

Date: September 28, 2009. 

Time: 10 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817 (Telephone Conference 

Call). 

Contact Person: Wendy F. Davidson, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIH/NIAID/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892–7616, 301– 

402–8399, davidsonw@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–21791 Filed 9–9–09; 8:45 am] 

BILLING CODE 4140–01–P 


erowe on DSK5CLS3C1PROD with NOTICES